Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes

Quan Zhang, Reshma Ramracheya, Carolina Lahmann, Andrei Tarasov, Martin Bengtsson, Orit Braha, Matthias Braun, Melissa Brereton, Stephan Collins, Juris Galvanovskis, Alejandro Gonzalez, Lukas N. Groschner, Nils J.G. Rorsman, Albert Salehi, Mary E. Travers, Jonathan N. Walker, Anna L. Gloyn, Fiona Gribble, Paul R.V. Johnson, Frank ReimannFrances M. Ashcroft, Patrik Rorsman

Research output: Contribution to journalArticlepeer-review

162 Citations (Scopus)

Abstract

Glucagon, secreted by pancreatic islet α cells, is the principal hyperglycemic hormone. In diabetes, glucagon secretion is not suppressed at high glucose, exacerbating the consequences of insufficient insulin secretion, and is inadequate at low glucose, potentially leading to fatal hypoglycemia. The causal mechanisms remain unknown. Here we show that α cell K ATP-channel activity is very low under hypoglycemic conditions and that hyperglycemia, via elevated intracellular ATP/ADP, leads to complete inhibition. This produces membrane depolarization and voltage-dependent inactivation of the Na+ channels involved in action potential firing that, via reduced action potential height and Ca2+ entry, suppresses glucagon secretion. Maneuvers that increase KATP channel activity, such as metabolic inhibition, mimic the glucagon secretory defects associated with diabetes. Low concentrations of the KATP channel blocker tolbutamide partially restore glucose-regulated glucagon secretion in islets from type 2 diabetic organ donors. These data suggest that impaired metabolic control of the KATP channels underlies the defective glucose regulation of glucagon secretion in type 2 diabetes.

Original languageEnglish
Pages (from-to)871-882
Number of pages12
JournalCell Metabolism
Volume18
Issue number6
DOIs
Publication statusPublished (in print/issue) - 3 Dec 2013

Fingerprint

Dive into the research topics of 'Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes'. Together they form a unique fingerprint.

Cite this